

1 AN ACT concerning regulation.

2 **Be it enacted by the People of the State of Illinois,**
3 **represented in the General Assembly:**

4 Section 5. The Clinical Psychologist Licensing Act is
5 amended by changing Sections 2, 7, and 15 and by adding
6 Sections 4.2, 4.3, and 4.5 as follows:

7 (225 ILCS 15/2) (from Ch. 111, par. 5352)

8 (Section scheduled to be repealed on January 1, 2017)

9 Sec. 2. Definitions. As used in this Act:

10 (1) "Department" means the Department of Financial and
11 Professional Regulation.

12 (2) "Secretary" means the Secretary of Financial and
13 Professional Regulation.

14 (3) "Board" means the Clinical Psychologists Licensing
15 and Disciplinary Board appointed by the Secretary.

16 (4) "Person" means an individual, association,
17 partnership or corporation.

18 (5) "Clinical psychology" means the independent
19 evaluation, classification and treatment of mental,
20 emotional, behavioral or nervous disorders or conditions,
21 developmental disabilities, alcoholism and substance
22 abuse, disorders of habit or conduct, the psychological
23 aspects of physical illness. The practice of clinical

1 psychology includes psychoeducational evaluation, therapy,
2 remediation and consultation, the use of psychological and
3 neuropsychological testing, assessment, psychotherapy,
4 psychoanalysis, hypnosis, biofeedback, and behavioral
5 modification when any of these are used for the purpose of
6 preventing or eliminating psychopathology, or for the
7 amelioration of psychological disorders of individuals or
8 groups. "Clinical psychology" does not include the use of
9 hypnosis by unlicensed persons pursuant to Section 3.

10 (6) A person represents himself to be a "clinical
11 psychologist" or "psychologist" within the meaning of this
12 Act when he or she holds himself out to the public by any
13 title or description of services incorporating the words
14 "psychological", "psychologic", "psychologist",
15 "psychology", or "clinical psychologist" or under such
16 title or description offers to render or renders clinical
17 psychological services as defined in paragraph (7) of this
18 Section to individuals, corporations, or the public for
19 remuneration.

20 (7) "Clinical psychological services" refers to any
21 services under paragraph (5) of this Section if the words
22 "psychological", "psychologic", "psychologist",
23 "psychology" or "clinical psychologist" are used to
24 describe such services by the person or organization
25 offering to render or rendering them.

26 (8) "Collaborating physician" means a physician

1 licensed to practice medicine in all of its branches in
2 Illinois who generally prescribes medications for the
3 treatment of mental health disease or illness to his or her
4 patients in the normal course of his or her clinical
5 medical practice.

6 (9) "Prescribing psychologist" means a licensed,
7 doctoral level psychologist who has undergone specialized
8 training, has passed an examination as determined by rule,
9 and has received a current license granting prescriptive
10 authority under Section 4.2 of this Act that has not been
11 revoked or suspended from the Department.

12 (10) "Prescriptive authority" means the authority to
13 prescribe, administer, discontinue, or distribute drugs or
14 medicines.

15 (11) "Prescription" means an order for a drug,
16 laboratory test, or any medicines, including controlled
17 substances as defined in the Illinois Controlled
18 Substances Act.

19 (12) "Drugs" has the meaning given to that term in the
20 Pharmacy Practice Act.

21 (13) "Medicines" has the meaning given to that term in
22 the Pharmacy Practice Act.

23 This Act shall not apply to persons lawfully carrying on
24 their particular profession or business under any valid
25 existing regulatory Act of the State.

26 (Source: P.A. 94-870, eff. 6-16-06.)

1 (225 ILCS 15/4.2 new)

2 Sec. 4.2. Prescribing psychologist license.

3 (a) A psychologist may apply to the Department for a
4 prescribing psychologist license. The application shall be
5 made on a form approved by the Department, include the payment
6 of any required fees, and be accompanied by evidence
7 satisfactory to the Department that the applicant:

8 (1) holds a current license to practice clinical
9 psychology in Illinois;

10 (2) has successfully completed the following minimum
11 educational and training requirements either during the
12 doctoral program required for licensure under this Section
13 or in an accredited undergraduate or master level program
14 prior to or subsequent to the doctoral program required
15 under this Section:

16 (A) specific minimum undergraduate biomedical
17 prerequisite coursework, including, but not limited
18 to: Medical Terminology (class or proficiency);
19 Chemistry or Biochemistry with lab (2 semesters);
20 Human Physiology (one semester); Human Anatomy (one
21 semester); Anatomy and Physiology; Microbiology with
22 lab (one semester); and General Biology for science
23 majors or Cell and Molecular Biology (one semester);

24 (B) a minimum of 60 credit hours of didactic
25 coursework, including, but not limited to:

Pharmacology; Clinical Psychopharmacology; Clinical
Anatomy and Integrated Science; Patient Evaluation;
Advanced Physical Assessment; Research Methods;
Advanced Pathophysiology; Diagnostic Methods; Problem
Based Learning; and Clinical and Procedural Skills;
and

(C) a full-time practicum of 14 months supervised
clinical training of at least 36 credit hours,
including a research project; during the clinical
rotation phase, students complete rotations in
Emergency Medicine, Family Medicine, Geriatrics,
Internal Medicine, Obstetrics and Gynecology,
Pediatrics, Psychiatrics, Surgery, and one elective of
the students' choice; program approval standards
addressing faculty qualifications, regular competency
evaluation and length of clinical rotations, and
instructional settings, including hospitals, hospital
outpatient clinics, community mental health clinics,
and correctional facilities, in accordance with those
of the Accreditation Review Commission on Education
for the Physician Assistant shall be set by Department
by rule;

(3) has completed a National Certifying Exam, as
determined by rule; and

(4) meets all other requirements for obtaining a
prescribing psychologist license, as determined by rule.

1 (b) The Department may issue a prescribing psychologist
2 license if it finds that the applicant has met the requirements
3 of subsection (a) of this Section.

4 (c) A prescribing psychologist may only prescribe
5 medication pursuant to the provisions of this Act if the
6 prescribing psychologist:

7 (1) continues to hold a current license to practice
8 psychology in Illinois;

9 (2) satisfies the continuing education requirements
10 for prescribing psychologists, including 10 hours of
11 continuing education annually in pharmacology from
12 accredited providers; and

13 (3) maintains a written collaborative agreement with a
14 collaborating physician pursuant to Section 4.3 of this
15 Act.

16 (225 ILCS 15/4.3 new)

17 Sec. 4.3. Written collaborative agreements.

18 (a) A written collaborative agreement is required for all
19 prescribing psychologists practicing under a prescribing
20 psychologist license issued pursuant to Section 4.2 of this
21 Act.

22 (b) A written delegation of prescriptive authority by a
23 collaborating physician may only include medications for the
24 treatment of mental health disease or illness the collaborating
25 physician generally provides to his or her patients in the

1 normal course of his or her clinical practice with the
2 exception of the following:

3 (1) patients who are less than 17 years of age or over
4 65 years of age;

5 (2) patients during pregnancy;

6 (3) patients with serious medical conditions, such as
7 heart disease, cancer, stroke, or seizures, and with
8 developmental disabilities and intellectual disabilities;
9 and

10 (4) prescriptive authority for benzodiazepine Schedule
11 III controlled substances.

12 (c) The collaborating physician shall file with the
13 Department notice of delegation of prescriptive authority and
14 termination of the delegation, in accordance with rules of the
15 Department. Upon receipt of this notice delegating authority to
16 prescribe any nonnarcotic Schedule III through V controlled
17 substances, the licensed clinical psychologist shall be
18 eligible to register for a mid-level practitioner controlled
19 substance license under Section 303.05 of the Illinois
20 Controlled Substances Act.

21 (d) All of the following shall apply to delegation of
22 prescriptive authority:

23 (1) Any delegation of Schedule III through V controlled
24 substances shall identify the specific controlled
25 substance by brand name or generic name. No controlled
26 substance to be delivered by injection may be delegated. No

1 Schedule II controlled substance shall be delegated.

2 (2) A prescribing psychologist shall not prescribe
3 narcotic drugs, as defined in Section 102 of the Illinois
4 Controlled Substances Act.

5 Any prescribing psychologist who writes a prescription for
6 a controlled substance without having valid and appropriate
7 authority may be fined by the Department not more than \$50 per
8 prescription and the Department may take any other disciplinary
9 action provided for in this Act.

10 (e) The written collaborative agreement shall describe the
11 working relationship of the prescribing psychologist with the
12 collaborating physician and shall delegate prescriptive
13 authority as provided in this Act. Collaboration does not
14 require an employment relationship between the collaborating
15 physician and prescribing psychologist. Absent an employment
16 relationship, an agreement may not restrict third-party
17 payment sources accepted by the prescribing psychologist. For
18 the purposes of this Section, "collaboration" means the
19 relationship between a prescribing psychologist and a
20 collaborating physician with respect to the delivery of
21 prescribing services in accordance with (1) the prescribing
22 psychologist's training, education, and experience and (2)
23 collaboration and consultation as documented in a jointly
24 developed written collaborative agreement.

25 (f) The agreement shall promote the exercise of
26 professional judgment by the prescribing psychologist

1 corresponding to his or her education and experience.

2 (g) The collaborative agreement shall not be construed to
3 require the personal presence of a physician at the place where
4 services are rendered. Methods of communication shall be
5 available for consultation with the collaborating physician in
6 person or by telecommunications in accordance with established
7 written guidelines as set forth in the written agreement.

8 (h) Collaboration and consultation pursuant to all
9 collaboration agreements shall be adequate if a collaborating
10 physician does each of the following:

11 (1) participates in the joint formulation and joint
12 approval of orders or guidelines with the prescribing
13 psychologist and he or she periodically reviews the
14 prescribing psychologist's orders and the services
15 provided patients under the orders in accordance with
16 accepted standards of medical practice and prescribing
17 psychologist practice;

18 (2) provides collaboration and consultation with the
19 prescribing psychologist in person at least once a month
20 for review of safety and quality clinical care or
21 treatment;

22 (3) is available through telecommunications for
23 consultation on medical problems, complications,
24 emergencies, or patient referral; and

25 (4) reviews medication orders of the prescribing
26 psychologist no less than monthly, including review of

1 laboratory tests and other tests as available.

2 (i) The written collaborative agreement shall contain
3 provisions detailing notice for termination or change of status
4 involving a written collaborative agreement, except when the
5 notice is given for just cause.

6 (j) A copy of the signed written collaborative agreement
7 shall be available to the Department upon request to either the
8 prescribing psychologist or the collaborating physician.

9 (k) Nothing in this Section shall be construed to limit the
10 authority of a prescribing psychologist to perform all duties
11 authorized under this Act.

12 (l) A prescribing psychologist shall inform each
13 collaborating physician of all collaborative agreements he or
14 she has signed and provide a copy of these to any collaborating
15 physician.

16 (m) No collaborating physician shall enter into more than 3
17 collaborative agreements with prescribing psychologists.

18 (225 ILCS 15/4.5 new)

19 Sec. 4.5. Endorsement.

20 (a) Individuals who are already licensed as medical or
21 prescribing psychologists in another state may apply for an
22 Illinois prescribing psychologist license by endorsement from
23 that state, or acceptance of that state's examination if they
24 meet the requirements set forth in this Act and its rules,
25 including proof of successful completion of the educational,

1 testing, and experience standards. Applicants from other
2 states may not be required to pass the examination required for
3 licensure as a prescribing psychologist in Illinois if they
4 meet requirements set forth in this Act and its rules, such as
5 proof of education, testing, payment of any fees, and
6 experience.

7 (b) Individuals who graduated from the Department of
8 Defense Psychopharmacology Demonstration Project may apply for
9 an Illinois prescribing psychologist license by endorsement.
10 Applicants from the Department of Defense Psychopharmacology
11 Demonstration Project may not be required to pass the
12 examination required for licensure as a prescribing
13 psychologist in Illinois if they meet requirements set forth in
14 this Act and its rules, such as proof of education, testing,
15 payment of any fees, and experience.

16 (c) Individuals applying for a prescribing psychologist
17 license by endorsement shall be required to first obtain a
18 clinical psychologist license under this Act.

19 (225 ILCS 15/7) (from Ch. 111, par. 5357)

20 (Section scheduled to be repealed on January 1, 2017)

21 Sec. 7. Board. The Secretary shall appoint a Board that
22 shall serve in an advisory capacity to the Secretary.

23 The Board shall consist of 11 ~~7~~ persons; ~~7~~ 4 of whom are
24 licensed clinical psychologists, ~~7~~ and actively engaged in the
25 practice of clinical psychology; 2 of whom are licensed

1 prescribing psychologists; 2 of whom are physicians licensed to
2 practice medicine in all its branches in Illinois who generally
3 prescribe medications for the treatment of mental health
4 disease or illness in the normal course of clinical medical
5 practice, one of whom shall be a psychiatrist and the other a
6 primary care or family physician; 7 2 of whom are licensed
7 clinical psychologists and are full time faculty members of
8 accredited colleges or universities who are engaged in training
9 clinical psychologists; 8 and one of whom is a public member who
10 is not a licensed health care provider. In appointing members
11 of the Board, the Secretary shall give due consideration to the
12 adequate representation of the various fields of health care
13 psychology such as clinical psychology, school psychology and
14 counseling psychology. In appointing members of the Board, the
15 Secretary shall give due consideration to recommendations by
16 members of the profession of clinical psychology and by the
17 State-wide organizations representing the interests of
18 clinical psychologists and organizations representing the
19 interests of academic programs as well as recommendations by
20 approved doctoral level psychology programs in the State of
21 Illinois, and, with respect to the 2 physician members of the
22 Board, the Secretary shall give due consideration to
23 recommendations by the Statewide professional associations or
24 societies representing physicians licensed to practice
25 medicine in all its branches in Illinois. The members shall be
26 appointed for a term of 4 years. No member shall be eligible to

1 serve for more than 2 full terms. Any appointment to fill a
2 vacancy shall be for the unexpired portion of the term. A
3 member appointed to fill a vacancy for an unexpired term for a
4 duration of 2 years or more may be reappointed for a maximum of
5 one term and a member appointed to fill a vacancy for an
6 unexpired term for a duration of less than 2 years may be
7 reappointed for a maximum of 2 terms. The Secretary may remove
8 any member for cause at any time prior to the expiration of his
9 or her term.

10 The 2 initial appointees to the Board who are licensed
11 prescribing psychologists may hold a medical or prescription
12 license issued by another state so long as the license is
13 deemed by the Secretary to be substantially equivalent to a
14 prescribing psychologist license under this Act and so long as
15 the appointees also maintain an Illinois clinical psychologist
16 license. Such initial appointees shall serve on the Board until
17 the Department adopts rules necessary to implement licensure
18 under Section 4.2 of this Act.

19 The Board shall annually elect one of its members as
20 chairperson and vice chairperson.

21 The members of the Board shall be reimbursed for all
22 authorized legitimate and necessary expenses incurred in
23 attending the meetings of the Board.

24 The Secretary shall give due consideration to all
25 recommendations of the Board. In the event the Secretary
26 disagrees with or takes action contrary to the recommendation

1 of the Board, he or she shall provide the Board with a written
2 and specific explanation of his or her actions.

3 The Board may make recommendations on all matters relating
4 to continuing education including the number of hours necessary
5 for license renewal, waivers for those unable to meet such
6 requirements and acceptable course content. Such
7 recommendations shall not impose an undue burden on the
8 Department or an unreasonable restriction on those seeking
9 license renewal.

10 The 2 licensed prescribing psychologist members of the
11 Board and the 2 physician members of the Board shall only
12 deliberate and make recommendations related to the licensure
13 and discipline of prescribing psychologists. Four members
14 shall constitute a quorum, except that all deliberations and
15 recommendations related to the licensure and discipline of
16 prescribing psychologists shall require a quorum of 6 members.

17 A quorum is required for all Board decisions.

18 Members of the Board shall have no liability in any action
19 based upon any disciplinary proceeding or other activity
20 performed in good faith as a member of the Board.

21 The Secretary may terminate the appointment of any member
22 for cause which in the opinion of the Secretary reasonably
23 justifies such termination.

24 (Source: P.A. 96-1050, eff. 1-1-11.)

1 (Section scheduled to be repealed on January 1, 2017)

2 Sec. 15. Disciplinary action; grounds. The Department may
3 refuse to issue, refuse to renew, suspend, or revoke any
4 license, or may place on probation, censure, reprimand, or take
5 other disciplinary action deemed appropriate by the
6 Department, including the imposition of fines not to exceed
7 \$10,000 for each violation, with regard to any license issued
8 under the provisions of this Act for any one or a combination
9 of the following reasons:

10 (1) Conviction of, or entry of a plea of guilty or nolo
11 contendere to, any crime that is a felony under the laws of
12 the United States or any state or territory thereof or that
13 is a misdemeanor of which an essential element is
14 dishonesty, or any crime that is directly related to the
15 practice of the profession.

16 (2) Gross negligence in the rendering of clinical
17 psychological services.

18 (3) Using fraud or making any misrepresentation in
19 applying for a license or in passing the examination
20 provided for in this Act.

21 (4) Aiding or abetting or conspiring to aid or abet a
22 person, not a clinical psychologist licensed under this
23 Act, in representing himself or herself as so licensed or
24 in applying for a license under this Act.

25 (5) Violation of any provision of this Act or the rules
26 promulgated thereunder.

1 (6) Professional connection or association with any
2 person, firm, association, partnership or corporation
3 holding himself, herself, themselves, or itself out in any
4 manner contrary to this Act.

5 (7) Unethical, unauthorized or unprofessional conduct
6 as defined by rule. In establishing those rules, the
7 Department shall consider, though is not bound by, the
8 ethical standards for psychologists promulgated by
9 recognized national psychology associations.

10 (8) Aiding or assisting another person in violating any
11 provisions of this Act or the rules promulgated thereunder.

12 (9) Failing to provide, within 60 days, information in
13 response to a written request made by the Department.

14 (10) Habitual or excessive use or addiction to alcohol,
15 narcotics, stimulants, or any other chemical agent or drug
16 that results in a clinical psychologist's inability to
17 practice with reasonable judgment, skill or safety.

18 (11) Discipline by another state, territory, the
19 District of Columbia or foreign country, if at least one of
20 the grounds for the discipline is the same or substantially
21 equivalent to those set forth herein.

22 (12) Directly or indirectly giving or receiving from
23 any person, firm, corporation, association or partnership
24 any fee, commission, rebate, or other form of compensation
25 for any professional service not actually or personally
26 rendered. Nothing in this paragraph (12) affects any bona

1 fide independent contractor or employment arrangements
2 among health care professionals, health facilities, health
3 care providers, or other entities, except as otherwise
4 prohibited by law. Any employment arrangements may include
5 provisions for compensation, health insurance, pension, or
6 other employment benefits for the provision of services
7 within the scope of the licensee's practice under this Act.
8 Nothing in this paragraph (12) shall be construed to
9 require an employment arrangement to receive professional
10 fees for services rendered.

11 (13) A finding by the Board that the licensee, after
12 having his or her license placed on probationary status has
13 violated the terms of probation.

14 (14) Willfully making or filing false records or
15 reports, including but not limited to, false records or
16 reports filed with State agencies or departments.

17 (15) Physical illness, including but not limited to,
18 deterioration through the aging process, mental illness or
19 disability that results in the inability to practice the
20 profession with reasonable judgment, skill and safety.

21 (16) Willfully failing to report an instance of
22 suspected child abuse or neglect as required by the Abused
23 and Neglected Child Reporting Act.

24 (17) Being named as a perpetrator in an indicated
25 report by the Department of Children and Family Services
26 pursuant to the Abused and Neglected Child Reporting Act,

1 and upon proof by clear and convincing evidence that the
2 licensee has caused a child to be an abused child or
3 neglected child as defined in the Abused and Neglected
4 Child Reporting Act.

5 (18) Violation of the Health Care Worker Self-Referral
6 Act.

7 (19) Making a material misstatement in furnishing
8 information to the Department, any other State or federal
9 agency, or any other entity.

10 (20) Failing to report to the Department any adverse
11 judgment, settlement, or award arising from a liability
12 claim related to an act or conduct similar to an act or
13 conduct that would constitute grounds for action as set
14 forth in this Section.

15 (21) Failing to report to the Department any adverse
16 final action taken against a licensee or applicant by
17 another licensing jurisdiction, including any other state
18 or territory of the United States or any foreign state or
19 country, or any peer review body, health care institution,
20 professional society or association related to the
21 profession, governmental agency, law enforcement agency,
22 or court for an act or conduct similar to an act or conduct
23 that would constitute grounds for disciplinary action as
24 set forth in this Section.

25 (22) Prescribing, selling, administering,
26 distributing, giving, or self-administering (A) any drug

1 classified as a controlled substance (designated product)
2 for other than medically accepted therapeutic purposes or
3 (B) any narcotic drug.

4 (23) Violating state or federal laws or regulations
5 relating to controlled substances, legend drugs, or
6 ephedra as defined in the Ephedra Prohibition Act.

7 (24) Exceeding the terms of a collaborative agreement
8 or the prescriptive authority delegated to a licensee by
9 his or her collaborating physician or established under a
10 written collaborative agreement.

11 The entry of an order by any circuit court establishing
12 that any person holding a license under this Act is subject to
13 involuntary admission or judicial admission as provided for in
14 the Mental Health and Developmental Disabilities Code,
15 operates as an automatic suspension of that license. That
16 person may have his or her license restored only upon the
17 determination by a circuit court that the patient is no longer
18 subject to involuntary admission or judicial admission and the
19 issuance of an order so finding and discharging the patient and
20 upon the Board's recommendation to the Department that the
21 license be restored. Where the circumstances so indicate, the
22 Board may recommend to the Department that it require an
23 examination prior to restoring any license so automatically
24 suspended.

25 The Department may refuse to issue or may suspend the
26 license of any person who fails to file a return, or to pay the

1 tax, penalty or interest shown in a filed return, or to pay any
2 final assessment of the tax penalty or interest, as required by
3 any tax Act administered by the Illinois Department of Revenue,
4 until such time as the requirements of any such tax Act are
5 satisfied.

6 In enforcing this Section, the Board upon a showing of a
7 possible violation may compel any person licensed to practice
8 under this Act, or who has applied for licensure or
9 certification pursuant to this Act, to submit to a mental or
10 physical examination, or both, as required by and at the
11 expense of the Department. The examining physicians or clinical
12 psychologists shall be those specifically designated by the
13 Board. The Board or the Department may order the examining
14 physician or clinical psychologist to present testimony
15 concerning this mental or physical examination of the licensee
16 or applicant. No information shall be excluded by reason of any
17 common law or statutory privilege relating to communications
18 between the licensee or applicant and the examining physician
19 or clinical psychologist. The person to be examined may have,
20 at his or her own expense, another physician or clinical
21 psychologist of his or her choice present during all aspects of
22 the examination. Failure of any person to submit to a mental or
23 physical examination, when directed, shall be grounds for
24 suspension of a license until the person submits to the
25 examination if the Board finds, after notice and hearing, that
26 the refusal to submit to the examination was without reasonable

1 cause.

2 If the Board finds a person unable to practice because of
3 the reasons set forth in this Section, the Board may require
4 that person to submit to care, counseling or treatment by
5 physicians or clinical psychologists approved or designated by
6 the Board, as a condition, term, or restriction for continued,
7 reinstated, or renewed licensure to practice; or, in lieu of
8 care, counseling or treatment, the Board may recommend to the
9 Department to file a complaint to immediately suspend, revoke
10 or otherwise discipline the license of the person. Any person
11 whose license was granted, continued, reinstated, renewed,
12 disciplined or supervised subject to such terms, conditions or
13 restrictions, and who fails to comply with such terms,
14 conditions or restrictions, shall be referred to the Secretary
15 for a determination as to whether the person shall have his or
16 her license suspended immediately, pending a hearing by the
17 Board.

18 In instances in which the Secretary immediately suspends a
19 person's license under this Section, a hearing on that person's
20 license must be convened by the Board within 15 days after the
21 suspension and completed without appreciable delay. The Board
22 shall have the authority to review the subject person's record
23 of treatment and counseling regarding the impairment, to the
24 extent permitted by applicable federal statutes and
25 regulations safeguarding the confidentiality of medical
26 records.

1 A person licensed under this Act and affected under this
2 Section shall be afforded an opportunity to demonstrate to the
3 Board that he or she can resume practice in compliance with
4 acceptable and prevailing standards under the provisions of his
5 or her license.

6 (Source: P.A. 96-1482, eff. 11-29-10.)

7 Section 10. The Medical Practice Act of 1987 is amended by
8 changing Sections 22 and 54.5 as follows:

9 (225 ILCS 60/22) (from Ch. 111, par. 4400-22)

10 (Section scheduled to be repealed on December 31, 2014)

11 Sec. 22. Disciplinary action.

12 (A) The Department may revoke, suspend, place on probation,
13 reprimand, refuse to issue or renew, or take any other
14 disciplinary or non-disciplinary action as the Department may
15 deem proper with regard to the license or permit of any person
16 issued under this Act to practice medicine, or a chiropractic
17 physician, including imposing fines not to exceed \$10,000 for
18 each violation, upon any of the following grounds:

19 (1) Performance of an elective abortion in any place,
20 locale, facility, or institution other than:

21 (a) a facility licensed pursuant to the Ambulatory
22 Surgical Treatment Center Act;

23 (b) an institution licensed under the Hospital
24 Licensing Act;

1 (c) an ambulatory surgical treatment center or
2 hospitalization or care facility maintained by the
3 State or any agency thereof, where such department or
4 agency has authority under law to establish and enforce
5 standards for the ambulatory surgical treatment
6 centers, hospitalization, or care facilities under its
7 management and control;

8 (d) ambulatory surgical treatment centers,
9 hospitalization or care facilities maintained by the
10 Federal Government; or

11 (e) ambulatory surgical treatment centers,
12 hospitalization or care facilities maintained by any
13 university or college established under the laws of
14 this State and supported principally by public funds
15 raised by taxation.

16 (2) Performance of an abortion procedure in a wilful
17 and wanton manner on a woman who was not pregnant at the
18 time the abortion procedure was performed.

19 (3) A plea of guilty or nolo contendere, finding of
20 guilt, jury verdict, or entry of judgment or sentencing,
21 including, but not limited to, convictions, preceding
22 sentences of supervision, conditional discharge, or first
23 offender probation, under the laws of any jurisdiction of
24 the United States of any crime that is a felony.

25 (4) Gross negligence in practice under this Act.

26 (5) Engaging in dishonorable, unethical or

1 unprofessional conduct of a character likely to deceive,
2 defraud or harm the public.

3 (6) Obtaining any fee by fraud, deceit, or
4 misrepresentation.

5 (7) Habitual or excessive use or abuse of drugs defined
6 in law as controlled substances, of alcohol, or of any
7 other substances which results in the inability to practice
8 with reasonable judgment, skill or safety.

9 (8) Practicing under a false or, except as provided by
10 law, an assumed name.

11 (9) Fraud or misrepresentation in applying for, or
12 procuring, a license under this Act or in connection with
13 applying for renewal of a license under this Act.

14 (10) Making a false or misleading statement regarding
15 their skill or the efficacy or value of the medicine,
16 treatment, or remedy prescribed by them at their direction
17 in the treatment of any disease or other condition of the
18 body or mind.

19 (11) Allowing another person or organization to use
20 their license, procured under this Act, to practice.

21 (12) Disciplinary action of another state or
22 jurisdiction against a license or other authorization to
23 practice as a medical doctor, doctor of osteopathy, doctor
24 of osteopathic medicine or doctor of chiropractic, a
25 certified copy of the record of the action taken by the
26 other state or jurisdiction being prima facie evidence

1 thereof.

2 (13) Violation of any provision of this Act or of the
3 Medical Practice Act prior to the repeal of that Act, or
4 violation of the rules, or a final administrative action of
5 the Secretary, after consideration of the recommendation
6 of the Disciplinary Board.

7 (14) Violation of the prohibition against fee
8 splitting in Section 22.2 of this Act.

9 (15) A finding by the Disciplinary Board that the
10 registrant after having his or her license placed on
11 probationary status or subjected to conditions or
12 restrictions violated the terms of the probation or failed
13 to comply with such terms or conditions.

14 (16) Abandonment of a patient.

15 (17) Prescribing, selling, administering,
16 distributing, giving or self-administering any drug
17 classified as a controlled substance (designated product)
18 or narcotic for other than medically accepted therapeutic
19 purposes.

20 (18) Promotion of the sale of drugs, devices,
21 appliances or goods provided for a patient in such manner
22 as to exploit the patient for financial gain of the
23 physician.

24 (19) Offering, undertaking or agreeing to cure or treat
25 disease by a secret method, procedure, treatment or
26 medicine, or the treating, operating or prescribing for any

1 human condition by a method, means or procedure which the
2 licensee refuses to divulge upon demand of the Department.

3 (20) Immoral conduct in the commission of any act
4 including, but not limited to, commission of an act of
5 sexual misconduct related to the licensee's practice.

6 (21) Wilfully making or filing false records or reports
7 in his or her practice as a physician, including, but not
8 limited to, false records to support claims against the
9 medical assistance program of the Department of Healthcare
10 and Family Services (formerly Department of Public Aid)
11 under the Illinois Public Aid Code.

12 (22) Wilful omission to file or record, or wilfully
13 impeding the filing or recording, or inducing another
14 person to omit to file or record, medical reports as
15 required by law, or wilfully failing to report an instance
16 of suspected abuse or neglect as required by law.

17 (23) Being named as a perpetrator in an indicated
18 report by the Department of Children and Family Services
19 under the Abused and Neglected Child Reporting Act, and
20 upon proof by clear and convincing evidence that the
21 licensee has caused a child to be an abused child or
22 neglected child as defined in the Abused and Neglected
23 Child Reporting Act.

24 (24) Solicitation of professional patronage by any
25 corporation, agents or persons, or profiting from those
26 representing themselves to be agents of the licensee.

1 (25) Gross and wilful and continued overcharging for
2 professional services, including filing false statements
3 for collection of fees for which services are not rendered,
4 including, but not limited to, filing such false statements
5 for collection of monies for services not rendered from the
6 medical assistance program of the Department of Healthcare
7 and Family Services (formerly Department of Public Aid)
8 under the Illinois Public Aid Code.

9 (26) A pattern of practice or other behavior which
10 demonstrates incapacity or incompetence to practice under
11 this Act.

12 (27) Mental illness or disability which results in the
13 inability to practice under this Act with reasonable
14 judgment, skill or safety.

15 (28) Physical illness, including, but not limited to,
16 deterioration through the aging process, or loss of motor
17 skill which results in a physician's inability to practice
18 under this Act with reasonable judgment, skill or safety.

19 (29) Cheating on or attempt to subvert the licensing
20 examinations administered under this Act.

21 (30) Wilfully or negligently violating the
22 confidentiality between physician and patient except as
23 required by law.

24 (31) The use of any false, fraudulent, or deceptive
25 statement in any document connected with practice under
26 this Act.

1 (32) Aiding and abetting an individual not licensed
2 under this Act in the practice of a profession licensed
3 under this Act.

4 (33) Violating state or federal laws or regulations
5 relating to controlled substances, legend drugs, or
6 ephedra as defined in the Ephedra Prohibition Act.

7 (34) Failure to report to the Department any adverse
8 final action taken against them by another licensing
9 jurisdiction (any other state or any territory of the
10 United States or any foreign state or country), by any peer
11 review body, by any health care institution, by any
12 professional society or association related to practice
13 under this Act, by any governmental agency, by any law
14 enforcement agency, or by any court for acts or conduct
15 similar to acts or conduct which would constitute grounds
16 for action as defined in this Section.

17 (35) Failure to report to the Department surrender of a
18 license or authorization to practice as a medical doctor, a
19 doctor of osteopathy, a doctor of osteopathic medicine, or
20 doctor of chiropractic in another state or jurisdiction, or
21 surrender of membership on any medical staff or in any
22 medical or professional association or society, while
23 under disciplinary investigation by any of those
24 authorities or bodies, for acts or conduct similar to acts
25 or conduct which would constitute grounds for action as
26 defined in this Section.

1 (36) Failure to report to the Department any adverse
2 judgment, settlement, or award arising from a liability
3 claim related to acts or conduct similar to acts or conduct
4 which would constitute grounds for action as defined in
5 this Section.

6 (37) Failure to provide copies of medical records as
7 required by law.

8 (38) Failure to furnish the Department, its
9 investigators or representatives, relevant information,
10 legally requested by the Department after consultation
11 with the Chief Medical Coordinator or the Deputy Medical
12 Coordinator.

13 (39) Violating the Health Care Worker Self-Referral
14 Act.

15 (40) Willful failure to provide notice when notice is
16 required under the Parental Notice of Abortion Act of 1995.

17 (41) Failure to establish and maintain records of
18 patient care and treatment as required by this law.

19 (42) Entering into an excessive number of written
20 collaborative agreements with licensed advanced practice
21 nurses resulting in an inability to adequately
22 collaborate.

23 (43) Repeated failure to adequately collaborate with a
24 licensed advanced practice nurse.

25 (44) Violating the Compassionate Use of Medical
26 Cannabis Pilot Program Act.

1 (45) Entering into an excessive number of written
2 collaborative agreements with licensed prescribing
3 psychologists resulting in an inability to adequately
4 collaborate.

5 (46) Repeated failure to adequately collaborate with a
6 licensed prescribing psychologist.

7 Except for actions involving the ground numbered (26), all
8 proceedings to suspend, revoke, place on probationary status,
9 or take any other disciplinary action as the Department may
10 deem proper, with regard to a license on any of the foregoing
11 grounds, must be commenced within 5 years next after receipt by
12 the Department of a complaint alleging the commission of or
13 notice of the conviction order for any of the acts described
14 herein. Except for the grounds numbered (8), (9), (26), and
15 (29), no action shall be commenced more than 10 years after the
16 date of the incident or act alleged to have violated this
17 Section. For actions involving the ground numbered (26), a
18 pattern of practice or other behavior includes all incidents
19 alleged to be part of the pattern of practice or other behavior
20 that occurred, or a report pursuant to Section 23 of this Act
21 received, within the 10-year period preceding the filing of the
22 complaint. In the event of the settlement of any claim or cause
23 of action in favor of the claimant or the reduction to final
24 judgment of any civil action in favor of the plaintiff, such
25 claim, cause of action or civil action being grounded on the
26 allegation that a person licensed under this Act was negligent

1 in providing care, the Department shall have an additional
2 period of 2 years from the date of notification to the
3 Department under Section 23 of this Act of such settlement or
4 final judgment in which to investigate and commence formal
5 disciplinary proceedings under Section 36 of this Act, except
6 as otherwise provided by law. The time during which the holder
7 of the license was outside the State of Illinois shall not be
8 included within any period of time limiting the commencement of
9 disciplinary action by the Department.

10 The entry of an order or judgment by any circuit court
11 establishing that any person holding a license under this Act
12 is a person in need of mental treatment operates as a
13 suspension of that license. That person may resume their
14 practice only upon the entry of a Departmental order based upon
15 a finding by the Disciplinary Board that they have been
16 determined to be recovered from mental illness by the court and
17 upon the Disciplinary Board's recommendation that they be
18 permitted to resume their practice.

19 The Department may refuse to issue or take disciplinary
20 action concerning the license of any person who fails to file a
21 return, or to pay the tax, penalty or interest shown in a filed
22 return, or to pay any final assessment of tax, penalty or
23 interest, as required by any tax Act administered by the
24 Illinois Department of Revenue, until such time as the
25 requirements of any such tax Act are satisfied as determined by
26 the Illinois Department of Revenue.

1 The Department, upon the recommendation of the
2 Disciplinary Board, shall adopt rules which set forth standards
3 to be used in determining:

4 (a) when a person will be deemed sufficiently
5 rehabilitated to warrant the public trust;

6 (b) what constitutes dishonorable, unethical or
7 unprofessional conduct of a character likely to deceive,
8 defraud, or harm the public;

9 (c) what constitutes immoral conduct in the commission
10 of any act, including, but not limited to, commission of an
11 act of sexual misconduct related to the licensee's
12 practice; and

13 (d) what constitutes gross negligence in the practice
14 of medicine.

15 However, no such rule shall be admissible into evidence in
16 any civil action except for review of a licensing or other
17 disciplinary action under this Act.

18 In enforcing this Section, the Disciplinary Board or the
19 Licensing Board, upon a showing of a possible violation, may
20 compel, in the case of the Disciplinary Board, any individual
21 who is licensed to practice under this Act or holds a permit to
22 practice under this Act, or, in the case of the Licensing
23 Board, any individual who has applied for licensure or a permit
24 pursuant to this Act, to submit to a mental or physical
25 examination and evaluation, or both, which may include a
26 substance abuse or sexual offender evaluation, as required by

1 the Licensing Board or Disciplinary Board and at the expense of
2 the Department. The Disciplinary Board or Licensing Board shall
3 specifically designate the examining physician licensed to
4 practice medicine in all of its branches or, if applicable, the
5 multidisciplinary team involved in providing the mental or
6 physical examination and evaluation, or both. The
7 multidisciplinary team shall be led by a physician licensed to
8 practice medicine in all of its branches and may consist of one
9 or more or a combination of physicians licensed to practice
10 medicine in all of its branches, licensed chiropractic
11 physicians, licensed clinical psychologists, licensed clinical
12 social workers, licensed clinical professional counselors, and
13 other professional and administrative staff. Any examining
14 physician or member of the multidisciplinary team may require
15 any person ordered to submit to an examination and evaluation
16 pursuant to this Section to submit to any additional
17 supplemental testing deemed necessary to complete any
18 examination or evaluation process, including, but not limited
19 to, blood testing, urinalysis, psychological testing, or
20 neuropsychological testing. The Disciplinary Board, the
21 Licensing Board, or the Department may order the examining
22 physician or any member of the multidisciplinary team to
23 provide to the Department, the Disciplinary Board, or the
24 Licensing Board any and all records, including business
25 records, that relate to the examination and evaluation,
26 including any supplemental testing performed. The Disciplinary

1 Board, the Licensing Board, or the Department may order the
2 examining physician or any member of the multidisciplinary team
3 to present testimony concerning this examination and
4 evaluation of the licensee, permit holder, or applicant,
5 including testimony concerning any supplemental testing or
6 documents relating to the examination and evaluation. No
7 information, report, record, or other documents in any way
8 related to the examination and evaluation shall be excluded by
9 reason of any common law or statutory privilege relating to
10 communication between the licensee or applicant and the
11 examining physician or any member of the multidisciplinary
12 team. No authorization is necessary from the licensee, permit
13 holder, or applicant ordered to undergo an evaluation and
14 examination for the examining physician or any member of the
15 multidisciplinary team to provide information, reports,
16 records, or other documents or to provide any testimony
17 regarding the examination and evaluation. The individual to be
18 examined may have, at his or her own expense, another physician
19 of his or her choice present during all aspects of the
20 examination. Failure of any individual to submit to mental or
21 physical examination and evaluation, or both, when directed,
22 shall result in an automatic suspension, without hearing, until
23 such time as the individual submits to the examination. If the
24 Disciplinary Board finds a physician unable to practice because
25 of the reasons set forth in this Section, the Disciplinary
26 Board shall require such physician to submit to care,

1 counseling, or treatment by physicians approved or designated
2 by the Disciplinary Board, as a condition for continued,
3 reinstated, or renewed licensure to practice. Any physician,
4 whose license was granted pursuant to Sections 9, 17, or 19 of
5 this Act, or, continued, reinstated, renewed, disciplined or
6 supervised, subject to such terms, conditions or restrictions
7 who shall fail to comply with such terms, conditions or
8 restrictions, or to complete a required program of care,
9 counseling, or treatment, as determined by the Chief Medical
10 Coordinator or Deputy Medical Coordinators, shall be referred
11 to the Secretary for a determination as to whether the licensee
12 shall have their license suspended immediately, pending a
13 hearing by the Disciplinary Board. In instances in which the
14 Secretary immediately suspends a license under this Section, a
15 hearing upon such person's license must be convened by the
16 Disciplinary Board within 15 days after such suspension and
17 completed without appreciable delay. The Disciplinary Board
18 shall have the authority to review the subject physician's
19 record of treatment and counseling regarding the impairment, to
20 the extent permitted by applicable federal statutes and
21 regulations safeguarding the confidentiality of medical
22 records.

23 An individual licensed under this Act, affected under this
24 Section, shall be afforded an opportunity to demonstrate to the
25 Disciplinary Board that they can resume practice in compliance
26 with acceptable and prevailing standards under the provisions

1 of their license.

2 The Department may promulgate rules for the imposition of
3 fines in disciplinary cases, not to exceed \$10,000 for each
4 violation of this Act. Fines may be imposed in conjunction with
5 other forms of disciplinary action, but shall not be the
6 exclusive disposition of any disciplinary action arising out of
7 conduct resulting in death or injury to a patient. Any funds
8 collected from such fines shall be deposited in the Medical
9 Disciplinary Fund.

10 All fines imposed under this Section shall be paid within
11 60 days after the effective date of the order imposing the fine
12 or in accordance with the terms set forth in the order imposing
13 the fine.

14 (B) The Department shall revoke the license or permit
15 issued under this Act to practice medicine or a chiropractic
16 physician who has been convicted a second time of committing
17 any felony under the Illinois Controlled Substances Act or the
18 Methamphetamine Control and Community Protection Act, or who
19 has been convicted a second time of committing a Class 1 felony
20 under Sections 8A-3 and 8A-6 of the Illinois Public Aid Code. A
21 person whose license or permit is revoked under this subsection
22 B shall be prohibited from practicing medicine or treating
23 human ailments without the use of drugs and without operative
24 surgery.

25 (C) The Disciplinary Board shall recommend to the
26 Department civil penalties and any other appropriate

1 discipline in disciplinary cases when the Board finds that a
2 physician willfully performed an abortion with actual
3 knowledge that the person upon whom the abortion has been
4 performed is a minor or an incompetent person without notice as
5 required under the Parental Notice of Abortion Act of 1995.
6 Upon the Board's recommendation, the Department shall impose,
7 for the first violation, a civil penalty of \$1,000 and for a
8 second or subsequent violation, a civil penalty of \$5,000.
9 (Source: P.A. 97-622, eff. 11-23-11; 98-601, eff. 12-30-13.)

10 (225 ILCS 60/54.5)

11 (Section scheduled to be repealed on December 31, 2014)

12 Sec. 54.5. Physician delegation of authority to physician
13 assistants, ~~and~~ advanced practice nurses, and prescribing
14 psychologists.

15 (a) Physicians licensed to practice medicine in all its
16 branches may delegate care and treatment responsibilities to a
17 physician assistant under guidelines in accordance with the
18 requirements of the Physician Assistant Practice Act of 1987. A
19 physician licensed to practice medicine in all its branches may
20 enter into supervising physician agreements with no more than 5
21 physician assistants as set forth in subsection (a) of Section
22 7 of the Physician Assistant Practice Act of 1987.

23 (b) A physician licensed to practice medicine in all its
24 branches in active clinical practice may collaborate with an
25 advanced practice nurse in accordance with the requirements of

1 the Nurse Practice Act. Collaboration is for the purpose of
2 providing medical consultation, and no employment relationship
3 is required. A written collaborative agreement shall conform to
4 the requirements of Section 65-35 of the Nurse Practice Act.
5 The written collaborative agreement shall be for services the
6 collaborating physician generally provides or may provide in
7 his or her clinical medical practice. A written collaborative
8 agreement shall be adequate with respect to collaboration with
9 advanced practice nurses if all of the following apply:

10 (1) The agreement is written to promote the exercise of
11 professional judgment by the advanced practice nurse
12 commensurate with his or her education and experience. The
13 agreement need not describe the exact steps that an
14 advanced practice nurse must take with respect to each
15 specific condition, disease, or symptom, but must specify
16 those procedures that require a physician's presence as the
17 procedures are being performed.

18 (2) Practice guidelines and orders are developed and
19 approved jointly by the advanced practice nurse and
20 collaborating physician, as needed, based on the practice
21 of the practitioners. Such guidelines and orders and the
22 patient services provided thereunder are periodically
23 reviewed by the collaborating physician.

24 (3) The advance practice nurse provides services the
25 collaborating physician generally provides or may provide
26 in his or her clinical medical practice, except as set

1 forth in subsection (b-5) of this Section. With respect to
2 labor and delivery, the collaborating physician must
3 provide delivery services in order to participate with a
4 certified nurse midwife.

5 (4) The collaborating physician and advanced practice
6 nurse consult at least once a month to provide
7 collaboration and consultation.

8 (5) Methods of communication are available with the
9 collaborating physician in person or through
10 telecommunications for consultation, collaboration, and
11 referral as needed to address patient care needs.

12 (6) The agreement contains provisions detailing notice
13 for termination or change of status involving a written
14 collaborative agreement, except when such notice is given
15 for just cause.

16 (b-5) An anesthesiologist or physician licensed to
17 practice medicine in all its branches may collaborate with a
18 certified registered nurse anesthetist in accordance with
19 Section 65-35 of the Nurse Practice Act for the provision of
20 anesthesia services. With respect to the provision of
21 anesthesia services, the collaborating anesthesiologist or
22 physician shall have training and experience in the delivery of
23 anesthesia services consistent with Department rules.
24 Collaboration shall be adequate if:

25 (1) an anesthesiologist or a physician participates in
26 the joint formulation and joint approval of orders or

1 guidelines and periodically reviews such orders and the
2 services provided patients under such orders; and

3 (2) for anesthesia services, the anesthesiologist or
4 physician participates through discussion of and agreement
5 with the anesthesia plan and is physically present and
6 available on the premises during the delivery of anesthesia
7 services for diagnosis, consultation, and treatment of
8 emergency medical conditions. Anesthesia services in a
9 hospital shall be conducted in accordance with Section 10.7
10 of the Hospital Licensing Act and in an ambulatory surgical
11 treatment center in accordance with Section 6.5 of the
12 Ambulatory Surgical Treatment Center Act.

13 (b-10) The anesthesiologist or operating physician must
14 agree with the anesthesia plan prior to the delivery of
15 services.

16 (c) The supervising physician shall have access to the
17 medical records of all patients attended by a physician
18 assistant. The collaborating physician shall have access to the
19 medical records of all patients attended to by an advanced
20 practice nurse.

21 (d) (Blank).

22 (e) A physician shall not be liable for the acts or
23 omissions of a prescribing psychologist, physician assistant,
24 or advanced practice nurse solely on the basis of having signed
25 a supervision agreement or guidelines or a collaborative
26 agreement, an order, a standing medical order, a standing

1 delegation order, or other order or guideline authorizing a
2 prescribing psychologist, physician assistant, or advanced
3 practice nurse to perform acts, unless the physician has reason
4 to believe the prescribing psychologist, physician assistant,
5 or advanced practice nurse lacked the competency to perform the
6 act or acts or commits willful and wanton misconduct.

7 (f) A collaborating physician may, but is not required to,
8 delegate prescriptive authority to an advanced practice nurse
9 as part of a written collaborative agreement, and the
10 delegation of prescriptive authority shall conform to the
11 requirements of Section 65-40 of the Nurse Practice Act.

12 (g) A supervising physician may, but is not required to,
13 delegate prescriptive authority to a physician assistant as
14 part of a written supervision agreement, and the delegation of
15 prescriptive authority shall conform to the requirements of
16 Section 7.5 of the Physician Assistant Practice Act of 1987.

17 (h) For the purposes of this Section, "generally provides
18 or may provide in his or her clinical medical practice" means
19 categories of care or treatment, not specific tasks or duties,
20 that the physician provides individually or through delegation
21 to other persons so that the physician has the experience and
22 ability to provide collaboration and consultation. This
23 definition shall not be construed to prohibit an advanced
24 practice nurse from providing primary health treatment or care
25 within the scope of his or her training and experience,
26 including, but not limited to, health screenings, patient

1 histories, physical examinations, women's health examinations,
2 or school physicals that may be provided as part of the routine
3 practice of an advanced practice nurse or on a volunteer basis.

4 (i) A collaborating physician shall delegate prescriptive
5 authority to a prescribing psychologist as part of a written
6 collaborative agreement, and the delegation of prescriptive
7 authority shall conform to the requirements of Section 4.3 of
8 the Clinical Psychologist Licensing Act.

9 (Source: P.A. 97-358, eff. 8-12-11; 97-1071, eff. 8-24-12;
10 98-192, eff. 1-1-14.)

11 Section 15. The Illinois Controlled Substances Act is
12 amended by changing Sections 102 and 303.05 as follows:

13 (720 ILCS 570/102) (from Ch. 56 1/2, par. 1102)

14 Sec. 102. Definitions. As used in this Act, unless the
15 context otherwise requires:

16 (a) "Addict" means any person who habitually uses any drug,
17 chemical, substance or dangerous drug other than alcohol so as
18 to endanger the public morals, health, safety or welfare or who
19 is so far addicted to the use of a dangerous drug or controlled
20 substance other than alcohol as to have lost the power of self
21 control with reference to his or her addiction.

22 (b) "Administer" means the direct application of a
23 controlled substance, whether by injection, inhalation,
24 ingestion, or any other means, to the body of a patient,

1 research subject, or animal (as defined by the Humane
2 Euthanasia in Animal Shelters Act) by:

3 (1) a practitioner (or, in his or her presence, by his
4 or her authorized agent),

5 (2) the patient or research subject pursuant to an
6 order, or

7 (3) a euthanasia technician as defined by the Humane
8 Euthanasia in Animal Shelters Act.

9 (c) "Agent" means an authorized person who acts on behalf
10 of or at the direction of a manufacturer, distributor,
11 dispenser, prescriber, or practitioner. It does not include a
12 common or contract carrier, public warehouseman or employee of
13 the carrier or warehouseman.

14 (c-1) "Anabolic Steroids" means any drug or hormonal
15 substance, chemically and pharmacologically related to
16 testosterone (other than estrogens, progestins,
17 corticosteroids, and dehydroepiandrosterone), and includes:

18 (i) 3[beta] ,17-dihydroxy-5a-androstane,

19 (ii) 3[alpha] ,17[beta] -dihydroxy-5a-androstane,

20 (iii) 5[alpha] -androstan-3,17-dione,

21 (iv) 1-androstenediol (3[beta] ,

22 17[beta] -dihydroxy-5[alpha] -androst-1-ene),

23 (v) 1-androstenediol (3[alpha] ,

24 17[beta] -dihydroxy-5[alpha] -androst-1-ene),

25 (vi) 4-androstenediol

26 (3[beta] ,17[beta] -dihydroxy-androst-4-ene),

(vii) 5-androstenediol
(3[beta] ,17[beta] -dihydroxy-androst-5-ene),
(viii) 1-androstenedione
([5alpha] -androst-1-en-3,17-dione),
(ix) 4-androstenedione
(androst-4-en-3,17-dione),
(x) 5-androstenedione
(androst-5-en-3,17-dione),
(xi) bolasterone (7[alpha] ,17a-dimethyl-17[beta] -
hydroxyandrost-4-en-3-one),
(xii) boldenone (17[beta] -hydroxyandrost-
1,4,-diene-3-one),
(xiii) boldione (androsta-1,4-
diene-3,17-dione),
(xiv) calusterone (7[beta] ,17[alpha] -dimethyl-17
[beta] -hydroxyandrost-4-en-3-one),
(xv) clostebol (4-chloro-17[beta] -
hydroxyandrost-4-en-3-one),
(xvi) dehydrochloromethyltestosterone (4-chloro-
17[beta] -hydroxy-17[alpha] -methyl-
androst-1,4-dien-3-one),
(xvii) desoxymethyltestosterone
(17[alpha] -methyl-5[alpha]
-androst-2-en-17[beta] -ol) (a.k.a., madol),
(xviii) [delta] 1-dihydrotestosterone (a.k.a.
'1-testosterone') (17[beta] -hydroxy-

1 5[alpha] -androst-1-en-3-one),
2 (xix) 4-dihydrotestosterone (17[beta] -hydroxy-
3 androstan-3-one),
4 (xx) drostanolone (17[beta] -hydroxy-2[alpha] -methyl-
5 5[alpha] -androstan-3-one),
6 (xxi) ethylestrenol (17[alpha] -ethyl-17[beta] -
7 hydroxyestr-4-ene),
8 (xxii) fluoxymesterone (9-fluoro-17[alpha] -methyl-
9 1[beta] , 17[beta] -dihydroxyandrost-4-en-3-one),
10 (xxiii) formebolone (2-formyl-17[alpha] -methyl-11[alpha] ,
11 17[beta] -dihydroxyandrost-1,4-dien-3-one),
12 (xxiv) furazabol (17[alpha] -methyl-17[beta] -
13 hydroxyandrostan[2,3-c] -furazan),
14 (xxv) 13[beta] -ethyl-17[beta] -hydroxygon-4-en-3-one)
15 (xxvi) 4-hydroxytestosterone (4,17[beta] -dihydroxy-
16 androst-4-en-3-one),
17 (xxvii) 4-hydroxy-19-nortestosterone (4,17[beta] -
18 dihydroxy-estr-4-en-3-one),
19 (xxviii) mestanolone (17[alpha] -methyl-17[beta] -
20 hydroxy-5-androstan-3-one),
21 (xxix) mesterolone (1-methyl-17[beta] -hydroxy-
22 [5a] -androstan-3-one),
23 (xxx) methandienone (17[alpha] -methyl-17[beta] -
24 hydroxyandrost-1,4-dien-3-one),
25 (xxxi) methandriol (17[alpha] -methyl-3[beta] , 17[beta] -
26 dihydroxyandrost-5-ene),

(xxxii) methenolone (1-methyl-17[beta] -hydroxy-
5[alpha] -androst-1-en-3-one),
(xxxiii) 17[alpha] -methyl-3[beta] , 17[beta] -
dihydroxy-5a-androstane),
(xxxiv) 17[alpha] -methyl-3[alpha] ,17[beta] -dihydroxy
-5a-androstane),
(xxxv) 17[alpha] -methyl-3[beta] ,17[beta] -
dihydroxyandrost-4-ene),
(xxxvi) 17[alpha] -methyl-4-hydroxynandrolone (17[alpha] -
methyl-4-hydroxy-17[beta] -hydroxyestr-4-en-3-one),
(xxxvii) methyldienolone (17[alpha] -methyl-17[beta] -
hydroxyestra-4,9(10)-dien-3-one),
(xxxviii) methyltrienolone (17[alpha] -methyl-17[beta] -
hydroxyestra-4,9-11-trien-3-one),
(xxxix) methyltestosterone (17[alpha] -methyl-17[beta] -
hydroxyandrost-4-en-3-one),
(xl) mibolerone (7[alpha] ,17a-dimethyl-17[beta] -
hydroxyestr-4-en-3-one),
(xli) 17[alpha] -methyl-[delta] 1-dihydrotestosterone
(17b[beta] -hydroxy-17[alpha] -methyl-5[alpha] -
androst-1-en-3-one) (a.k.a. '17-[alpha] -methyl-
1-testosterone'),
(xlii) nandrolone (17[beta] -hydroxyestr-4-en-3-one),
(xliii) 19-nor-4-androstenediol (3[beta] , 17[beta] -
dihydroxyestr-4-ene),
(xliv) 19-nor-4-androstenediol (3[alpha] , 17[beta] -

1 dihydroxyestr-4-ene),
2 (xlv) 19-nor-5-androstenediol (3[beta] , 17[beta] -
3 dihydroxyestr-5-ene),
4 (xlvi) 19-nor-5-androstenediol (3[alpha] , 17[beta] -
5 dihydroxyestr-5-ene),
6 (xlvii) 19-nor-4,9(10)-androstadienedione
7 (estra-4,9(10)-diene-3,17-dione),
8 (xlviii) 19-nor-4-androstenedione (estr-4-
9 en-3,17-dione),
10 (xlix) 19-nor-5-androstenedione (estr-5-
11 en-3,17-dione),
12 (li) norbolethone (13[beta] , 17a-diethyl-17[beta] -
13 hydroxygon-4-en-3-one),
14 (lii) norclostebol (4-chloro-17[beta] -
15 hydroxyestr-4-en-3-one),
16 (liii) norethandrolone (17[alpha] -ethyl-17[beta] -
17 hydroxyestr-4-en-3-one),
18 (liiii) normethandrolone (17[alpha] -methyl-17[beta] -
19 hydroxyestr-4-en-3-one),
20 (liv) oxandrolone (17[alpha] -methyl-17[beta] -hydroxy-
21 2-oxa-5[alpha] -androstan-3-one),
22 (lv) oxymesterone (17[alpha] -methyl-4,17[beta] -
23 dihydroxyandrost-4-en-3-one),
24 (lvi) oxymetholone (17[alpha] -methyl-2-hydroxymethylene-
25 17[beta] -hydroxy-(5[alpha] -androstan-3-one),
26 (lvii) stanozolol (17[alpha] -methyl-17[beta] -hydroxy-

(5[alpha] -androst-2-eno[3,2-c] -pyrazole),
(lviii) stenbolone (17[beta] -hydroxy-2-methyl-
(5[alpha] -androst-1-en-3-one),
(lix) testolactone (13-hydroxy-3-oxo-13,17-
secoandrosta-1,4-dien-17-oic
acid lactone),
(lx) testosterone (17[beta] -hydroxyandrost-
4-en-3-one),
(lxi) tetrahydrogestrinone (13[beta] , 17[alpha] -
diethyl-17[beta] -hydroxygon-
4,9,11-trien-3-one),
(lxii) trenbolone (17[beta] -hydroxyestr-4,9,
11-trien-3-one).

Any person who is otherwise lawfully in possession of an
anabolic steroid, or who otherwise lawfully manufactures,
distributes, dispenses, delivers, or possesses with intent to
deliver an anabolic steroid, which anabolic steroid is
expressly intended for and lawfully allowed to be administered
through implants to livestock or other nonhuman species, and
which is approved by the Secretary of Health and Human Services
for such administration, and which the person intends to
administer or have administered through such implants, shall
not be considered to be in unauthorized possession or to
unlawfully manufacture, distribute, dispense, deliver, or
possess with intent to deliver such anabolic steroid for
purposes of this Act.

1 (d) "Administration" means the Drug Enforcement
2 Administration, United States Department of Justice, or its
3 successor agency.

4 (d-5) "Clinical Director, Prescription Monitoring Program"
5 means a Department of Human Services administrative employee
6 licensed to either prescribe or dispense controlled substances
7 who shall run the clinical aspects of the Department of Human
8 Services Prescription Monitoring Program and its Prescription
9 Information Library.

10 (d-10) "Compounding" means the preparation and mixing of
11 components, excluding flavorings, (1) as the result of a
12 prescriber's prescription drug order or initiative based on the
13 prescriber-patient-pharmacist relationship in the course of
14 professional practice or (2) for the purpose of, or incident
15 to, research, teaching, or chemical analysis and not for sale
16 or dispensing. "Compounding" includes the preparation of drugs
17 or devices in anticipation of receiving prescription drug
18 orders based on routine, regularly observed dispensing
19 patterns. Commercially available products may be compounded
20 for dispensing to individual patients only if both of the
21 following conditions are met: (i) the commercial product is not
22 reasonably available from normal distribution channels in a
23 timely manner to meet the patient's needs and (ii) the
24 prescribing practitioner has requested that the drug be
25 compounded.

26 (e) "Control" means to add a drug or other substance, or

1 immediate precursor, to a Schedule whether by transfer from
2 another Schedule or otherwise.

3 (f) "Controlled Substance" means (i) a drug, substance, or
4 immediate precursor in the Schedules of Article II of this Act
5 or (ii) a drug or other substance, or immediate precursor,
6 designated as a controlled substance by the Department through
7 administrative rule. The term does not include distilled
8 spirits, wine, malt beverages, or tobacco, as those terms are
9 defined or used in the Liquor Control Act of 1934 and the
10 Tobacco Products Tax Act of 1995.

11 (f-5) "Controlled substance analog" means a substance:

12 (1) the chemical structure of which is substantially
13 similar to the chemical structure of a controlled substance
14 in Schedule I or II;

15 (2) which has a stimulant, depressant, or
16 hallucinogenic effect on the central nervous system that is
17 substantially similar to or greater than the stimulant,
18 depressant, or hallucinogenic effect on the central
19 nervous system of a controlled substance in Schedule I or
20 II; or

21 (3) with respect to a particular person, which such
22 person represents or intends to have a stimulant,
23 depressant, or hallucinogenic effect on the central
24 nervous system that is substantially similar to or greater
25 than the stimulant, depressant, or hallucinogenic effect
26 on the central nervous system of a controlled substance in

1 Schedule I or II.

2 (g) "Counterfeit substance" means a controlled substance,
3 which, or the container or labeling of which, without
4 authorization bears the trademark, trade name, or other
5 identifying mark, imprint, number or device, or any likeness
6 thereof, of a manufacturer, distributor, or dispenser other
7 than the person who in fact manufactured, distributed, or
8 dispensed the substance.

9 (h) "Deliver" or "delivery" means the actual, constructive
10 or attempted transfer of possession of a controlled substance,
11 with or without consideration, whether or not there is an
12 agency relationship.

13 (i) "Department" means the Illinois Department of Human
14 Services (as successor to the Department of Alcoholism and
15 Substance Abuse) or its successor agency.

16 (j) (Blank).

17 (k) "Department of Corrections" means the Department of
18 Corrections of the State of Illinois or its successor agency.

19 (l) "Department of Financial and Professional Regulation"
20 means the Department of Financial and Professional Regulation
21 of the State of Illinois or its successor agency.

22 (m) "Depressant" means any drug that (i) causes an overall
23 depression of central nervous system functions, (ii) causes
24 impaired consciousness and awareness, and (iii) can be
25 habit-forming or lead to a substance abuse problem, including
26 but not limited to alcohol, cannabis and its active principles

1 and their analogs, benzodiazepines and their analogs,
2 barbiturates and their analogs, opioids (natural and
3 synthetic) and their analogs, and chloral hydrate and similar
4 sedative hypnotics.

5 (n) (Blank).

6 (o) "Director" means the Director of the Illinois State
7 Police or his or her designated agents.

8 (p) "Dispense" means to deliver a controlled substance to
9 an ultimate user or research subject by or pursuant to the
10 lawful order of a prescriber, including the prescribing,
11 administering, packaging, labeling, or compounding necessary
12 to prepare the substance for that delivery.

13 (q) "Dispenser" means a practitioner who dispenses.

14 (r) "Distribute" means to deliver, other than by
15 administering or dispensing, a controlled substance.

16 (s) "Distributor" means a person who distributes.

17 (t) "Drug" means (1) substances recognized as drugs in the
18 official United States Pharmacopoeia, Official Homeopathic
19 Pharmacopoeia of the United States, or official National
20 Formulary, or any supplement to any of them; (2) substances
21 intended for use in diagnosis, cure, mitigation, treatment, or
22 prevention of disease in man or animals; (3) substances (other
23 than food) intended to affect the structure of any function of
24 the body of man or animals and (4) substances intended for use
25 as a component of any article specified in clause (1), (2), or
26 (3) of this subsection. It does not include devices or their

1 components, parts, or accessories.

2 (t-5) "Euthanasia agency" means an entity certified by the
3 Department of Financial and Professional Regulation for the
4 purpose of animal euthanasia that holds an animal control
5 facility license or animal shelter license under the Animal
6 Welfare Act. A euthanasia agency is authorized to purchase,
7 store, possess, and utilize Schedule II nonnarcotic and
8 Schedule III nonnarcotic drugs for the sole purpose of animal
9 euthanasia.

10 (t-10) "Euthanasia drugs" means Schedule II or Schedule III
11 substances (nonnarcotic controlled substances) that are used
12 by a euthanasia agency for the purpose of animal euthanasia.

13 (u) "Good faith" means the prescribing or dispensing of a
14 controlled substance by a practitioner in the regular course of
15 professional treatment to or for any person who is under his or
16 her treatment for a pathology or condition other than that
17 individual's physical or psychological dependence upon or
18 addiction to a controlled substance, except as provided herein:
19 and application of the term to a pharmacist shall mean the
20 dispensing of a controlled substance pursuant to the
21 prescriber's order which in the professional judgment of the
22 pharmacist is lawful. The pharmacist shall be guided by
23 accepted professional standards including, but not limited to
24 the following, in making the judgment:

25 (1) lack of consistency of prescriber-patient
26 relationship,

1 (2) frequency of prescriptions for same drug by one
2 prescriber for large numbers of patients,

3 (3) quantities beyond those normally prescribed,

4 (4) unusual dosages (recognizing that there may be
5 clinical circumstances where more or less than the usual
6 dose may be used legitimately),

7 (5) unusual geographic distances between patient,
8 pharmacist and prescriber,

9 (6) consistent prescribing of habit-forming drugs.

10 (u-0.5) "Hallucinogen" means a drug that causes markedly
11 altered sensory perception leading to hallucinations of any
12 type.

13 (u-1) "Home infusion services" means services provided by a
14 pharmacy in compounding solutions for direct administration to
15 a patient in a private residence, long-term care facility, or
16 hospice setting by means of parenteral, intravenous,
17 intramuscular, subcutaneous, or intraspinal infusion.

18 (u-5) "Illinois State Police" means the State Police of the
19 State of Illinois, or its successor agency.

20 (v) "Immediate precursor" means a substance:

21 (1) which the Department has found to be and by rule
22 designated as being a principal compound used, or produced
23 primarily for use, in the manufacture of a controlled
24 substance;

25 (2) which is an immediate chemical intermediary used or
26 likely to be used in the manufacture of such controlled

1 substance; and

2 (3) the control of which is necessary to prevent,
3 curtail or limit the manufacture of such controlled
4 substance.

5 (w) "Instructional activities" means the acts of teaching,
6 educating or instructing by practitioners using controlled
7 substances within educational facilities approved by the State
8 Board of Education or its successor agency.

9 (x) "Local authorities" means a duly organized State,
10 County or Municipal peace unit or police force.

11 (y) "Look-alike substance" means a substance, other than a
12 controlled substance which (1) by overall dosage unit
13 appearance, including shape, color, size, markings or lack
14 thereof, taste, consistency, or any other identifying physical
15 characteristic of the substance, would lead a reasonable person
16 to believe that the substance is a controlled substance, or (2)
17 is expressly or impliedly represented to be a controlled
18 substance or is distributed under circumstances which would
19 lead a reasonable person to believe that the substance is a
20 controlled substance. For the purpose of determining whether
21 the representations made or the circumstances of the
22 distribution would lead a reasonable person to believe the
23 substance to be a controlled substance under this clause (2) of
24 subsection (y), the court or other authority may consider the
25 following factors in addition to any other factor that may be
26 relevant:

1 (a) statements made by the owner or person in control
2 of the substance concerning its nature, use or effect;

3 (b) statements made to the buyer or recipient that the
4 substance may be resold for profit;

5 (c) whether the substance is packaged in a manner
6 normally used for the illegal distribution of controlled
7 substances;

8 (d) whether the distribution or attempted distribution
9 included an exchange of or demand for money or other
10 property as consideration, and whether the amount of the
11 consideration was substantially greater than the
12 reasonable retail market value of the substance.

13 Clause (1) of this subsection (y) shall not apply to a
14 noncontrolled substance in its finished dosage form that was
15 initially introduced into commerce prior to the initial
16 introduction into commerce of a controlled substance in its
17 finished dosage form which it may substantially resemble.

18 Nothing in this subsection (y) prohibits the dispensing or
19 distributing of noncontrolled substances by persons authorized
20 to dispense and distribute controlled substances under this
21 Act, provided that such action would be deemed to be carried
22 out in good faith under subsection (u) if the substances
23 involved were controlled substances.

24 Nothing in this subsection (y) or in this Act prohibits the
25 manufacture, preparation, propagation, compounding,
26 processing, packaging, advertising or distribution of a drug or

1 drugs by any person registered pursuant to Section 510 of the
2 Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).

3 (y-1) "Mail-order pharmacy" means a pharmacy that is
4 located in a state of the United States that delivers,
5 dispenses or distributes, through the United States Postal
6 Service or other common carrier, to Illinois residents, any
7 substance which requires a prescription.

8 (z) "Manufacture" means the production, preparation,
9 propagation, compounding, conversion or processing of a
10 controlled substance other than methamphetamine, either
11 directly or indirectly, by extraction from substances of
12 natural origin, or independently by means of chemical
13 synthesis, or by a combination of extraction and chemical
14 synthesis, and includes any packaging or repackaging of the
15 substance or labeling of its container, except that this term
16 does not include:

17 (1) by an ultimate user, the preparation or compounding
18 of a controlled substance for his or her own use; or

19 (2) by a practitioner, or his or her authorized agent
20 under his or her supervision, the preparation,
21 compounding, packaging, or labeling of a controlled
22 substance:

23 (a) as an incident to his or her administering or
24 dispensing of a controlled substance in the course of
25 his or her professional practice; or

26 (b) as an incident to lawful research, teaching or

1 chemical analysis and not for sale.

2 (z-1) (Blank).

3 (z-5) "Medication shopping" means the conduct prohibited
4 under subsection (a) of Section 314.5 of this Act.

5 (z-10) "Mid-level practitioner" means (i) a physician
6 assistant who has been delegated authority to prescribe through
7 a written delegation of authority by a physician licensed to
8 practice medicine in all of its branches, in accordance with
9 Section 7.5 of the Physician Assistant Practice Act of 1987,
10 (ii) an advanced practice nurse who has been delegated
11 authority to prescribe through a written delegation of
12 authority by a physician licensed to practice medicine in all
13 of its branches or by a podiatric physician, in accordance with
14 Section 65-40 of the Nurse Practice Act, ~~or~~ (iii) an animal
15 euthanasia agency, or (iv) a prescribing psychologist.

16 (aa) "Narcotic drug" means any of the following, whether
17 produced directly or indirectly by extraction from substances
18 of vegetable origin, or independently by means of chemical
19 synthesis, or by a combination of extraction and chemical
20 synthesis:

21 (1) opium, opiates, derivatives of opium and opiates,
22 including their isomers, esters, ethers, salts, and salts
23 of isomers, esters, and ethers, whenever the existence of
24 such isomers, esters, ethers, and salts is possible within
25 the specific chemical designation; however the term
26 "narcotic drug" does not include the isoquinoline

1 alkaloids of opium;

2 (2) (blank);

3 (3) opium poppy and poppy straw;

4 (4) coca leaves, except coca leaves and extracts of
5 coca leaves from which substantially all of the cocaine and
6 ecgonine, and their isomers, derivatives and salts, have
7 been removed;

8 (5) cocaine, its salts, optical and geometric isomers,
9 and salts of isomers;

10 (6) ecgonine, its derivatives, their salts, isomers,
11 and salts of isomers;

12 (7) any compound, mixture, or preparation which
13 contains any quantity of any of the substances referred to
14 in subparagraphs (1) through (6).

15 (bb) "Nurse" means a registered nurse licensed under the
16 Nurse Practice Act.

17 (cc) (Blank).

18 (dd) "Opiate" means any substance having an addiction
19 forming or addiction sustaining liability similar to morphine
20 or being capable of conversion into a drug having addiction
21 forming or addiction sustaining liability.

22 (ee) "Opium poppy" means the plant of the species *Papaver*
23 *somniferum* L., except its seeds.

24 (ee-5) "Oral dosage" means a tablet, capsule, elixir, or
25 solution or other liquid form of medication intended for
26 administration by mouth, but the term does not include a form

1 of medication intended for buccal, sublingual, or transmucosal
2 administration.

3 (ff) "Parole and Pardon Board" means the Parole and Pardon
4 Board of the State of Illinois or its successor agency.

5 (gg) "Person" means any individual, corporation,
6 mail-order pharmacy, government or governmental subdivision or
7 agency, business trust, estate, trust, partnership or
8 association, or any other entity.

9 (hh) "Pharmacist" means any person who holds a license or
10 certificate of registration as a registered pharmacist, a local
11 registered pharmacist or a registered assistant pharmacist
12 under the Pharmacy Practice Act.

13 (ii) "Pharmacy" means any store, ship or other place in
14 which pharmacy is authorized to be practiced under the Pharmacy
15 Practice Act.

16 (ii-5) "Pharmacy shopping" means the conduct prohibited
17 under subsection (b) of Section 314.5 of this Act.

18 (ii-10) "Physician" (except when the context otherwise
19 requires) means a person licensed to practice medicine in all
20 of its branches.

21 (jj) "Poppy straw" means all parts, except the seeds, of
22 the opium poppy, after mowing.

23 (kk) "Practitioner" means a physician licensed to practice
24 medicine in all its branches, dentist, optometrist, podiatric
25 physician, veterinarian, scientific investigator, pharmacist,
26 physician assistant, advanced practice nurse, licensed

1 practical nurse, registered nurse, hospital, laboratory, or
2 pharmacy, or other person licensed, registered, or otherwise
3 lawfully permitted by the United States or this State to
4 distribute, dispense, conduct research with respect to,
5 administer or use in teaching or chemical analysis, a
6 controlled substance in the course of professional practice or
7 research.

8 (ll) "Pre-printed prescription" means a written
9 prescription upon which the designated drug has been indicated
10 prior to the time of issuance; the term does not mean a written
11 prescription that is individually generated by machine or
12 computer in the prescriber's office.

13 (mm) "Prescriber" means a physician licensed to practice
14 medicine in all its branches, dentist, optometrist,
15 prescribing psychologist licensed under Section 4.2 of the
16 Clinical Psychologist Licensing Act with prescriptive
17 authority delegated under Section 4.3 of the Clinical
18 Psychologist Licensing Act, podiatric physician, or
19 veterinarian who issues a prescription, a physician assistant
20 who issues a prescription for a controlled substance in
21 accordance with Section 303.05, a written delegation, and a
22 written supervision agreement required under Section 7.5 of the
23 Physician Assistant Practice Act of 1987, or an advanced
24 practice nurse with prescriptive authority delegated under
25 Section 65-40 of the Nurse Practice Act and in accordance with
26 Section 303.05, a written delegation, and a written

1 collaborative agreement under Section 65-35 of the Nurse
2 Practice Act.

3 (nn) "Prescription" means a written, facsimile, or oral
4 order, or an electronic order that complies with applicable
5 federal requirements, of a physician licensed to practice
6 medicine in all its branches, dentist, podiatric physician or
7 veterinarian for any controlled substance, of an optometrist
8 for a Schedule III, IV, or V controlled substance in accordance
9 with Section 15.1 of the Illinois Optometric Practice Act of
10 1987, of a prescribing psychologist licensed under Section 4.2
11 of the Clinical Psychologist Licensing Act with prescriptive
12 authority delegated under Section 4.3 of the Clinical
13 Psychologist Licensing Act, of a physician assistant for a
14 controlled substance in accordance with Section 303.05, a
15 written delegation, and a written supervision agreement
16 required under Section 7.5 of the Physician Assistant Practice
17 Act of 1987, or of an advanced practice nurse with prescriptive
18 authority delegated under Section 65-40 of the Nurse Practice
19 Act who issues a prescription for a controlled substance in
20 accordance with Section 303.05, a written delegation, and a
21 written collaborative agreement under Section 65-35 of the
22 Nurse Practice Act when required by law.

23 (nn-5) "Prescription Information Library" (PIL) means an
24 electronic library that contains reported controlled substance
25 data.

26 (nn-10) "Prescription Monitoring Program" (PMP) means the

1 entity that collects, tracks, and stores reported data on
2 controlled substances and select drugs pursuant to Section 316.

3 (oo) "Production" or "produce" means manufacture,
4 planting, cultivating, growing, or harvesting of a controlled
5 substance other than methamphetamine.

6 (pp) "Registrant" means every person who is required to
7 register under Section 302 of this Act.

8 (qq) "Registry number" means the number assigned to each
9 person authorized to handle controlled substances under the
10 laws of the United States and of this State.

11 (qq-5) "Secretary" means, as the context requires, either
12 the Secretary of the Department or the Secretary of the
13 Department of Financial and Professional Regulation, and the
14 Secretary's designated agents.

15 (rr) "State" includes the State of Illinois and any state,
16 district, commonwealth, territory, insular possession thereof,
17 and any area subject to the legal authority of the United
18 States of America.

19 (rr-5) "Stimulant" means any drug that (i) causes an
20 overall excitation of central nervous system functions, (ii)
21 causes impaired consciousness and awareness, and (iii) can be
22 habit-forming or lead to a substance abuse problem, including
23 but not limited to amphetamines and their analogs,
24 methylphenidate and its analogs, cocaine, and phencyclidine
25 and its analogs.

26 (ss) "Ultimate user" means a person who lawfully possesses

1 a controlled substance for his or her own use or for the use of
2 a member of his or her household or for administering to an
3 animal owned by him or her or by a member of his or her
4 household.

5 (Source: P.A. 97-334, eff. 1-1-12; 98-214, eff. 8-9-13; revised
6 11-12-13.)

7 (720 ILCS 570/303.05)

8 Sec. 303.05. Mid-level practitioner registration.

9 (a) The Department of Financial and Professional
10 Regulation shall register licensed physician assistants, ~~and~~
11 licensed advanced practice nurses, and prescribing
12 psychologists licensed under Section 4.2 of the Clinical
13 Psychologist Licensing Act to prescribe and dispense
14 controlled substances under Section 303 and euthanasia
15 agencies to purchase, store, or administer animal euthanasia
16 drugs under the following circumstances:

17 (1) with respect to physician assistants,

18 (A) the physician assistant has been delegated
19 written authority to prescribe any Schedule III
20 through V controlled substances by a physician
21 licensed to practice medicine in all its branches in
22 accordance with Section 7.5 of the Physician Assistant
23 Practice Act of 1987; and the physician assistant has
24 completed the appropriate application forms and has
25 paid the required fees as set by rule; or

(B) the physician assistant has been delegated authority by a supervising physician licensed to practice medicine in all its branches to prescribe or dispense Schedule II controlled substances through a written delegation of authority and under the following conditions:

(i) Specific Schedule II controlled substances by oral dosage or topical or transdermal application may be delegated, provided that the delegated Schedule II controlled substances are routinely prescribed by the supervising physician. This delegation must identify the specific Schedule II controlled substances by either brand name or generic name. Schedule II controlled substances to be delivered by injection or other route of administration may not be delegated;

(ii) any delegation must be of controlled substances prescribed by the supervising physician;

(iii) all prescriptions must be limited to no more than a 30-day supply, with any continuation authorized only after prior approval of the supervising physician;

(iv) the physician assistant must discuss the condition of any patients for whom a controlled substance is prescribed monthly with the

1 delegating physician;

2 (v) the physician assistant must have
3 completed the appropriate application forms and
4 paid the required fees as set by rule;

5 (vi) the physician assistant must provide
6 evidence of satisfactory completion of 45 contact
7 hours in pharmacology from any physician assistant
8 program accredited by the Accreditation Review
9 Commission on Education for the Physician
10 Assistant (ARC-PA), or its predecessor agency, for
11 any new license issued with Schedule II authority
12 after the effective date of this amendatory Act of
13 the 97th General Assembly; and

14 (vii) the physician assistant must annually
15 complete at least 5 hours of continuing education
16 in pharmacology; ~~and~~

17 (2) with respect to advanced practice nurses,

18 (A) the advanced practice nurse has been delegated
19 authority to prescribe any Schedule III through V
20 controlled substances by a collaborating physician
21 licensed to practice medicine in all its branches or a
22 collaborating podiatric physician in accordance with
23 Section 65-40 of the Nurse Practice Act. The advanced
24 practice nurse has completed the appropriate
25 application forms and has paid the required fees as set
26 by rule; or

1 (B) the advanced practice nurse has been delegated
2 authority by a collaborating physician licensed to
3 practice medicine in all its branches or collaborating
4 podiatric physician to prescribe or dispense Schedule
5 II controlled substances through a written delegation
6 of authority and under the following conditions:

7 (i) specific Schedule II controlled substances
8 by oral dosage or topical or transdermal
9 application may be delegated, provided that the
10 delegated Schedule II controlled substances are
11 routinely prescribed by the collaborating
12 physician or podiatric physician. This delegation
13 must identify the specific Schedule II controlled
14 substances by either brand name or generic name.
15 Schedule II controlled substances to be delivered
16 by injection or other route of administration may
17 not be delegated;

18 (ii) any delegation must be of controlled
19 substances prescribed by the collaborating
20 physician or podiatric physician;

21 (iii) all prescriptions must be limited to no
22 more than a 30-day supply, with any continuation
23 authorized only after prior approval of the
24 collaborating physician or podiatric physician;

25 (iv) the advanced practice nurse must discuss
26 the condition of any patients for whom a controlled

1 substance is prescribed monthly with the
2 delegating physician or podiatric physician or in
3 the course of review as required by Section 65-40
4 of the Nurse Practice Act;

5 (v) the advanced practice nurse must have
6 completed the appropriate application forms and
7 paid the required fees as set by rule;

8 (vi) the advanced practice nurse must provide
9 evidence of satisfactory completion of at least 45
10 graduate contact hours in pharmacology for any new
11 license issued with Schedule II authority after
12 the effective date of this amendatory Act of the
13 97th General Assembly; and

14 (vii) the advanced practice nurse must
15 annually complete 5 hours of continuing education
16 in pharmacology; ~~or~~

17 (3) with respect to animal euthanasia agencies, the
18 euthanasia agency has obtained a license from the
19 Department of Financial and Professional Regulation and
20 obtained a registration number from the Department; ~~or~~

21 (4) with respect to prescribing psychologists, the
22 prescribing psychologist has been delegated authority to
23 prescribe any nonnarcotic Schedule III through V
24 controlled substances by a collaborating physician
25 licensed to practice medicine in all its branches in
26 accordance with Section 4.3 of the Clinical Psychologist

1 Licensing Act, and the prescribing psychologist has
2 completed the appropriate application forms and has paid
3 the required fees as set by rule.

4 (b) The mid-level practitioner shall only be licensed to
5 prescribe those schedules of controlled substances for which a
6 licensed physician or licensed podiatric physician has
7 delegated prescriptive authority, except that an animal
8 euthanasia agency does not have any prescriptive authority. A
9 physician assistant and an advanced practice nurse are
10 prohibited from prescribing medications and controlled
11 substances not set forth in the required written delegation of
12 authority.

13 (c) Upon completion of all registration requirements,
14 physician assistants, advanced practice nurses, and animal
15 euthanasia agencies may be issued a mid-level practitioner
16 controlled substances license for Illinois.

17 (d) A collaborating physician or podiatric physician may,
18 but is not required to, delegate prescriptive authority to an
19 advanced practice nurse as part of a written collaborative
20 agreement, and the delegation of prescriptive authority shall
21 conform to the requirements of Section 65-40 of the Nurse
22 Practice Act.

23 (e) A supervising physician may, but is not required to,
24 delegate prescriptive authority to a physician assistant as
25 part of a written supervision agreement, and the delegation of
26 prescriptive authority shall conform to the requirements of

1 Section 7.5 of the Physician Assistant Practice Act of 1987.

2 (f) Nothing in this Section shall be construed to prohibit
3 generic substitution.

4 (Source: P.A. 97-334, eff. 1-1-12; 97-358, eff. 8-12-11;
5 97-813, eff. 7-13-12; 98-214, eff. 8-9-13.)

6 Section 99. Effective date. This Act takes effect upon
7 becoming law.